Performance Status, Prognostic Scoring, and Parenteral Nutrition Requirements Predict Survival in Patients with Advanced Cancer Receiving Home Parenteral Nutrition

References

• Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al.: ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36, 11–48, 2017. doi: 10.1016/j.clnu.2016.07.015
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Molfino A, Laviano A, Rasio D, and Rossi Fanelli F: Parenteral nutrition in advanced cancer patients. Crit Rev Oncol Hematol 84, 26–36, 2012. doi: 10.1016/j.critrevonc.2012.01.005
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Santarpia L, Pironi L, Thul P, Klek S, et al.: The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients. Annals of Oncology 25, 487–493, 2014. doi: 10.1093/annonc/mdt549
   PubMed Web of Science ®Google Scholar
• Bukki J, Unterpaul T, Nubling G, Jox RJ, and Lorenzl S: Decision making at the end of life–cancer patients' and their caregivers' views on artificial nutrition and hydration. Support Care Cancer 22, 3287–3299, 2014. doi: 10.1007/s00520-014-2337-6
   PubMed Web of Science ®Google Scholar
• Bozzetti F: Nutrition, hydration, and patient's preferences at the end of life. Support Care Cancer 23, 1487–1488, 2015. doi: 10.1007/s00520-014-2591-7
   PubMed Web of Science ®Google Scholar
• Naghibi M, Smith TR, and Elia M: A systematic review with meta-analysis of survival, quality of life and cost-effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. Clin Nutr 34, 825–837, 2015. doi: 10.1016/j.clnu.2014.09.010
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, et al.: ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr 28, 445–454, 2009. doi: 10.1016/j.clnu.2009.04.011
   PubMed Web of Science ®Google Scholar
• Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, et al.: Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 25, 1492–1499, 2014. doi: 10.1093/annonc/mdu085
   PubMed Web of Science ®Google Scholar
• Fearon KC, Voss AC, Hustead DS, and Cancer Cachexia Study Group: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83, 1345–1350, 2006.
   PubMed Web of Science ®Google Scholar
• Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, et al.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33, 90–99, 2015. doi: 10.1200/JCO.2014.56.1894
   PubMed Web of Science ®Google Scholar
• Bozzetti F: Nutritional support of the oncology patient. Crit Rev Oncol Hematol 87, 172–200, 2013. doi: 10.1016/j.critrevonc.2013.03.006
   PubMed Web of Science ®Google Scholar
• Bukki J: Re: recommendations for bowel obstruction with peritoneal carcinomatosis by laval et Al. J Pain Symptom Manage 48, e5–e6, 2014. doi: 10.1016/j.jpainsymman.2014.07.006
   PubMed Web of Science ®Google Scholar
• Soo I, and Gramlich L: Use of parenteral nutrition in patients with advanced cancer. Appl Physiol Nutr Metab 33, 102–106, 2008. doi: 10.1139/H07-152
   PubMed Web of Science ®Google Scholar
• Mirhosseini M, and Fainsinger R: Parenteral nutrition in patients with advanced cancer #190. J Palliat Med 12, 260–261, 2009. doi: 10.1089/jpm.2009.9653
   PubMed Web of Science ®Google Scholar
• Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, Copel L, et al.: Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manage 48, 75–91, 2014. doi: 10.1016/j.jpainsymman.2013.08.022
   PubMed Web of Science ®Google Scholar
• Baxter JP, and McKee RF: The Scottish home parenteral nutrition managed clinical network: one year on. Clin Nutr 22, 501–504, 2003.
   PubMed Web of Science ®Google Scholar
• King LA, Carson LF, Konstantinides N, House MS, Adcock LL, et al.: Outcome assessment of home parenteral nutrition in patients with gynecologic malignancies: what have we learned in a decade of experience? Gynecol Oncol 51, 377–382, 1993. doi: 10.1006/gyno.1993.1307
   PubMed Web of Science ®Google Scholar
• Aria Guerra E, Cortes-Salgado A, Mateo-Lobo R, Nattero L, Riveiro J, et al.: Role of parenteral nutrition in oncologic patients with intestinal occlusion and peritoneal carcinomatosis. Nutr Hosp 32, 1222–1227, 2015. doi: 10.3305/nh.2015.32.3.9184
   PubMed Web of Science ®Google Scholar
• Scolapio JS, Fleming CR, Kelly DG, Wick DM, and Zinsmeister AR: Survival of home parenteral nutrition-treated patients: 20 years of experience at the mayo clinic. Mayo Clinic Proc 74, 217–222, 1999. doi: 10.4065/74.3.217
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Cozzaglio L, Biganzoli E, Chiavenna G, De Cicco M, et al.: Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin Nutr 21, 281–288, 2002.
   PubMed Web of Science ®Google Scholar
• Duerksen DR, Ting E, Thomson P, McCurdy K, Linscer J, et al.: Is there a role for TPN in terminally ill patients with bowel obstruction? Nutrition 20, 760–763, 2004. doi: 10.1016/j.nut.2004.05.010
   PubMed Web of Science ®Google Scholar
• Hoda D, Jatoi A, Burnes J, Loprinzi C, and Kelly D: Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? Cancer 103, 863–868, 2005. doi: 10.1002/cncr.20824
   PubMed Web of Science ®Google Scholar
• Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, et al.: The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 103, 176–180, 2006. doi: 10.1016/j.ygyno.2006.02.013
   PubMed Web of Science ®Google Scholar
• Chermesh I, Mashiach T, Amit A, Haim N, Papier I, et al.: Home parenteral nutrition (HTPN) for incurable patients with cancer with gastrointestinal obstruction: Do the benefits outweigh the risks? Med Oncol 28, 83–88, 2011. doi: 10.1007/s12032-010-9426-2
   PubMed Web of Science ®Google Scholar
• Bozzetti F, Cotogni P, Lo Vullo S, Pironi L, Giardiello D, et al.: Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition. Ann Oncol 26, 2335–2340, 2015. doi: 10.1093/annonc/mdv365
   PubMed Web of Science ®Google Scholar
• Fragkos K, Fini L, Keane N, Kwok H, Paulon E, et al.: PTU-109 Home parenteral nutrition in patients with advanced cancer: a systematic review. Gut 66, A104–A105, 2017. doi: 10.1136/gutjnl-2017-314472.204
   Web of Science ®Google Scholar
• Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, et al.: ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr 28, 467–479, 2009. doi: 10.1016/j.clnu.2009.04.001
   PubMed Web of Science ®Google Scholar
• Pironi L, Ruggeri E, Tanneberger S, Giordani S, Pannuti F, et al.: Home artificial nutrition in advanced cancer. J Royal Soc Med 90, 597–603, 1997.
   PubMed Web of Science ®Google Scholar
• Karnofsky DA, Abelmann WH, Craver LF, and Burchenal JH: The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinoma. Cancer 1, 634–656, 1948. doi: 10.1002/1097-0142(194811)1:4<634::aid-cncr2820010410>3.0.co;2-l
   Web of Science ®Google Scholar
• Schag CC, Heinrich RL, and Ganz PA: Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2, 187–193, 1984.
   PubMed Web of Science ®Google Scholar
• Hui D: Prognostication of survival in patients with advanced cancer: predicting the unpredictable? Cancer Control 22, 489–497, 2015.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489–495, 2011. doi: 10.1016/s1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Tian H, Yao X, Zeng R, Sun R, Tian H, et al.: Safety and efficacy of a new parenteral lipid emulsion (SMOF) for surgical patients: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71, 815–821, 2013. doi: 10.1111/nure.12053
   PubMed Web of Science ®Google Scholar
• Evans C, and McCarthy M: Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1, 1204–1206, 1985.
   PubMed Web of Science ®Google Scholar
• Matsunuma R, Tanbo Y, Asai N, Ohkuni Y, Watanabe S, et al.: Prognostic factors in patients with terminal stage lung cancer. J Palliat Med 17, 189–194, 2014. doi: 10.1089/jpm.2013.0448
   PubMed Web of Science ®Google Scholar
• Schonwetter RS, Robinson BE, and Ramirez G: Prognostic factors for survival in terminal lung cancer patients. J Gen Intern Med 9, 366–371, 1994.
   PubMed Web of Science ®Google Scholar
• Vigano A, Dorgan M, Buckingham J, and Bruera E: Suarez-Almazor ME: Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 14, 363–374, 2000.
   PubMed Web of Science ®Google Scholar
• Keane N, Fragkos KC, Patel PS, Obbard S, Murray K, et al.: MON-P068: An updated audit of home parenteral nutrition (hpn) in palliative oncology patients – A UK single centre case series with survival analysis. Clin Nutr 35, S178, 2016. doi: 10.1016/s0261-5614(16)30702-6
   Google Scholar
• Glare P, Sinclair C, Downing M, Stone P, Maltoni M, et al.: Predicting survival in patients with advanced disease. Eur J Cancer 44, 1146–1156, 2008. doi: 10.1016/j.ejca.2008.02.030
   PubMed Web of Science ®Google Scholar
• McMillan DC: The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39, 534–540, 2013. doi: 10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• Brown DJ, Milroy R, Preston T, and McMillan DC: The relationship between an inflammation-based prognostic score (glasgow prognostic score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 60, 705–708, 2007. doi: 10.1136/jcp.2005.033217
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, et al.: The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the glasgow inflammation outcome study. Br J Cancer 103, 870–876, 2010. doi: 10.1038/sj.bjc.6605855
   PubMed Web of Science ®Google Scholar
• Pantano Nde P, Paiva BS, Hui D, and Paiva CE: Validation of the modified glasgow prognostic score in advanced cancer patients receiving palliative care. J Pain Symptom Manage 51, 270–277, 2016. doi: 10.1016/j.jpainsymman.2015.09.010
   PubMed Web of Science ®Google Scholar
• Douglas E, and McMillan DC: Towards a simple objective framework for the investigation and treatment of cancer cachexia: the glasgow prognostic score. Cancer Treat Rev 40, 685–691, 2014. doi: S0305-7372(13)00260-0 [pii] 10.1016/j.ctrv.2013.11.007
   PubMed Web of Science ®Google Scholar
• Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, et al.: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations–a study by the steering committee of the European association for palliative care. J Clin Oncol 23, 6240–6248, 2005. doi: 10.1200/JCO.2005.06.866
   PubMed Web of Science ®Google Scholar